RxDoctor Payments Data

Pattara Rattanawong, MD

Cardiovascular Disease · Scottsdale, AZNPI 1972959385

Payments from drug & device makers

What this record shows

This record is dominated by grants: $27,993 of the $43,455 with a category attached, or 64.4%. 13 manufacturers reported payments, led by Abbott at 43.7% of the total. Reporting peaked in 2023 at $15,719 and has fallen 57.3% since, to $6,713 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$43,455in general payments, 2019–2025

Across 148 payments — averaging $293.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$19K
  • Medtronic$11K
  • Boston Scientific$9K
  • Biosense Webster, Inc.$2K
  • Medical Device Business Services, Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$551
  • plus $1K from 7 others

What the payments were for

  • Grants$27,99364%
  • Travel & lodging$4,71511%
  • Food & beverage$10,30424%
  • Education$4431%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,455 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$55,876
Medicare patients
150
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$18,994

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →